Multiple Sclerosis - Pipeline Review, H2 2016

 

Rating

4.8 Star Rating for report Multiple Sclerosis - Pipeline Review, H2 2016
4.8 / 5 stars rating
Pages: 928
Price: $2500.00

Some of our Clients

Some Research and Expert Clients

Abstract

 
Multiple sclerosis (MS) is a potentially debilitating disease in which body's immune system eats away at the protective sheath (myelin) that covers nerves. Damage to myelin causes interference in the communication between brain, spinal cord and other areas of body. Symptoms include numbness or weakness in one or more limbs, double vision or blurring of vision, tingling or pain in parts of body, fatigue and slurred speech. The predisposing factors include age, gender, family history and certain infections.  

Description

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Multiple Sclerosis - Pipeline Review, H2 2016, provides an overview of the Multiple Sclerosis (Central Nervous System) pipeline landscape.

Multiple sclerosis (MS) is a potentially debilitating disease in which body's immune system eats away at the protective sheath (myelin) that covers nerves. Damage to myelin causes interference in the communication between brain, spinal cord and other areas of body. Symptoms include numbness or weakness in one or more limbs, double vision or blurring of vision, tingling or pain in parts of body, fatigue and slurred speech. The predisposing factors include age, gender, family history and certain infections.
 

Similar Reports

Other reports that may be of interest...

Report... 05IB-GMDHC8907IDBMultiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-Sys...Dec 2016
Report... 05IB-GMDHC8884IDBProgressive Relapsing Multiple Sclerosis (PRMS) - Pipeline Revie...Dec 2016
Report... 05IB-GMDHC8855IDBProgressive Supranuclear Palsy - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8863IDBParkinson's Disease - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8861IDBNeuropathic Pain - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8832IDBSmoking Addiction - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8797IDBInfantile Spasm (West Syndrome) - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8796IDBMetachromatic Leukodystrophy (MLD) - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8799IDBEssential Tremor - Pipeline Review, H2 2016Dec 2016

Report Source Information

Supplied by: Research and Experts 
Date Published: 2016-12-21 

Report: Multiple Sclerosis - Pipeline Review, H2 2016

 

Contents

Table of Contents
Table of Contents 2
Introduction 10
Multiple Sclerosis Overview 11
Therapeutics Development 12
Multiple Sclerosis - Therapeutics under Development by Companies 14
Multiple Sclerosis - Therapeutics under Investigation by Universities/Institutes 31
Multiple Sclerosis - Pipeline Products Glance 34
Multiple Sclerosis - Products under Development by Companies 38
Multiple Sclerosis - Products under Investigation by Universities/Institutes 58
Multiple Sclerosis - Companies Involved in Therapeutics Development 62
Multiple Sclerosis - Therapeutics Assessment 250
Drug Profiles 291
Multiple Sclerosis - Dormant Projects 839
Multiple Sclerosis - Discontinued Products 864
Multiple Sclerosis - Product Development Milestones 869
Appendix 891
 

List of Tables

List of Tables
Number of Products under Development for Multiple Sclerosis, H2 2016 48
Number of Products under Development for Multiple Sclerosis - Comparative Analysis, H2 2016 49
Number of Products under Development by Companies, H2 2016 51
Number of Products under Development by Companies, H2 2016 (Contd..1) 52
Number of Products under Development by Companies, H2 2016 (Contd..2) 53
Number of Products under Development by Companies, H2 2016 (Contd..3) 54
Number of Products under Development by Companies, H2 2016 (Contd..4) 55
Number of Products under Development by Companies, H2 2016 (Contd..5) 56
Number of Products under Development by Companies, H2 2016 (Contd..6) 57
Number of Products under Development by Companies, H2 2016 (Contd..7) 58
Number of Products under Development by Companies, H2 2016 (Contd..8) 59
Number of Products under Development by Companies, H2 2016 (Contd..9) 60
Number of Products under Development by Companies, H2 2016 (Contd..10) 61
Number of Products under Development by Companies, H2 2016 (Contd..11) 62
Number of Products under Development by Companies, H2 2016 (Contd..12) 63
Number of Products under Development by Companies, H2 2016 (Contd..13) 64
Number of Products under Development by Companies, H2 2016 (Contd..14) 65
Number of Products under Development by Companies, H2 2016 (Contd..15) 66
Number of Products under Investigation by Universities/Institutes, H2 2016 67
Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 68
Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..2) 69
Comparative Analysis by Late Stage Development, H2 2016 70
Comparative Analysis by Clinical Stage Development, H2 2016 71
Comparative Analysis by Early Stage Development, H2 2016 72
Comparative Analysis by Unknown Stage Development, H2 2016 73
Products under Development by Companies, H2 2016 74
Products under Development by Companies, H2 2016 (Contd..1) 75
Products under Development by Companies, H2 2016 (Contd..2) 76
Products under Development by Companies, H2 2016 (Contd..3) 77
Products under Development by Companies, H2 2016 (Contd..4) 78
Products under Development by Companies, H2 2016 (Contd..5) 79
Products under Development by Companies, H2 2016 (Contd..6) 80
Products under Development by Companies, H2 2016 (Contd..7) 81
Products under Development by Companies, H2 2016 (Contd..8) 82
Products under Development by Companies, H2 2016 (Contd..9) 83
Products under Development by Companies, H2 2016 (Contd..10) 84
Products under Development by Companies, H2 2016 (Contd..11) 85
Products under Development by Companies, H2 2016 (Contd..12) 86
Products under Development by Companies, H2 2016 (Contd..13) 87
Products under Development by Companies, H2 2016 (Contd..14) 88
Products under Development by Companies, H2 2016 (Contd..15) 89
Products under Development by Companies, H2 2016 (Contd..16) 90
Products under Development by Companies, H2 2016 (Contd..17) 91
Products under Development by Companies, H2 2016 (Contd..18) 92
Products under Development by Companies, H2 2016 (Contd..19) 93
Products under Investigation by Universities/Institutes, H2 2016 94
Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 95
Products under Investigation by Universities/Institutes, H2 2016 (Contd..2) 96
Products under Investigation by Universities/Institutes, H2 2016 (Contd..3) 97
Multiple Sclerosis - Pipeline by 2-BBB Medicines BV, H2 2016 98
Multiple Sclerosis - Pipeline by 4D Pharma Plc, H2 2016 99
Multiple Sclerosis - Pipeline by AB Science SA, H2 2016 100
Multiple Sclerosis - Pipeline by AbbVie Inc, H2 2016 101
Multiple Sclerosis - Pipeline by Abion Inc, H2 2016 102
Multiple Sclerosis - Pipeline by Ablynx NV, H2 2016 103
Multiple Sclerosis - Pipeline by Abzena Plc, H2 2016 104
Multiple Sclerosis - Pipeline by Acorda Therapeutics Inc, H2 2016 105
Multiple Sclerosis - Pipeline by Actelion Ltd, H2 2016 106
Multiple Sclerosis - Pipeline by Adamas Pharmaceuticals Inc, H2 2016 107
Multiple Sclerosis - Pipeline by Addex Therapeutics Ltd, H2 2016 108
Multiple Sclerosis - Pipeline by Adhaere Pharmaceuticals Inc, H2 2016 109
Multiple Sclerosis - Pipeline by Aegis Therapeutics LLC, H2 2016 110
Multiple Sclerosis - Pipeline by Affectis Pharmaceuticals AG, H2 2016 111
Multiple Sclerosis - Pipeline by AiCuris GmbH & Co KG, H2 2016 112
Multiple Sclerosis - Pipeline by Alkermes Plc, H2 2016 113
Multiple Sclerosis - Pipeline by Alpha Cancer Technologies Inc, H2 2016 114
Multiple Sclerosis - Pipeline by Amarna Therapeutics BV, H2 2016 115
Multiple Sclerosis - Pipeline by Anavex Life Sciences Corp, H2 2016 116
Multiple Sclerosis - Pipeline by Antisense Therapeutics Ltd, H2 2016 117
Multiple Sclerosis - Pipeline by Aphios Corp, H2 2016 118
Multiple Sclerosis - Pipeline by Apitope International NV, H2 2016 119
Multiple Sclerosis - Pipeline by ARA Healthcare Pvt Ltd, H2 2016 120
Multiple Sclerosis - Pipeline by Arena Pharmaceuticals Inc, H2 2016 121
Multiple Sclerosis - Pipeline by arGEN-X BV, H2 2016 122
Multiple Sclerosis - Pipeline by Argos Therapeutics Inc, H2 2016 123
Multiple Sclerosis - Pipeline by Arrien Pharmaceuticals LLC, H2 2016 124
Multiple Sclerosis - Pipeline by Artielle ImmunoTherapeutics Inc, H2 2016 125
Multiple Sclerosis - Pipeline by Astellas Pharma Inc, H2 2016 126
Multiple Sclerosis - Pipeline by Asterias Biotherapeutics Inc, H2 2016 127
Multiple Sclerosis - Pipeline by Atara Biotherapeutics Inc, H2 2016 128
Multiple Sclerosis - Pipeline by Athersys Inc, H2 2016 129
Multiple Sclerosis - Pipeline by Atlantic Bio Sci LLC, H2 2016 130
Multiple Sclerosis - Pipeline by Axxam SpA, H2 2016 131
Multiple Sclerosis - Pipeline by Baliopharm AG, H2 2016 132
Multiple Sclerosis - Pipeline by Bio-Cancer Treatment International Ltd, H2 2016 133
Multiple Sclerosis - Pipeline by BioAegis Therapeutics Inc, H2 2016 134
Multiple Sclerosis - Pipeline by BioApex sro, H2 2016 135
Multiple Sclerosis - Pipeline by Biocad, H2 2016 136
Multiple Sclerosis - Pipeline by Biocon Ltd, H2 2016 137
Multiple Sclerosis - Pipeline by Biogen Inc, H2 2016 138
Multiple Sclerosis - Pipeline by Biogenomics Ltd, H2 2016 139
Multiple Sclerosis - Pipeline by BioHealthonomics Inc, H2 2016 140
Multiple Sclerosis - Pipeline by Biokine Therapeutics Ltd, H2 2016 141
Multiple Sclerosis - Pipeline by Biomar Microbial Technologies, H2 2016 142
Multiple Sclerosis - Pipeline by Bioncotech Therapeutics SL, H2 2016 143
Multiple Sclerosis - Pipeline by Bionovis SA, H2 2016 144
Multiple Sclerosis - Pipeline by Bionure Farma SL, H2 2016 145
Multiple Sclerosis - Pipeline by Biovista Inc, H2 2016 146
Multiple Sclerosis - Pipeline by Bolder Biotechnology Inc, H2 2016 147
Multiple Sclerosis - Pipeline by BrainStorm Cell Therapeutics Inc, H2 2016 148
Multiple Sclerosis - Pipeline by Bristol-Myers Squibb Company, H2 2016 149
Multiple Sclerosis - Pipeline by C4X Discovery Holdings PLC, H2 2016 150
Multiple Sclerosis - Pipeline by CASI Pharmaceuticals Inc, H2 2016 151
Multiple Sclerosis - Pipeline by Catalyst Pharmaceuticals Inc, H2 2016 152
Multiple Sclerosis - Pipeline by Celgene Corp, H2 2016 153
Multiple Sclerosis - Pipeline by Cell Cure Neurosciences Ltd, H2 2016 154
Multiple Sclerosis - Pipeline by Cell2B Advanced Therapeutics SA, H2 2016 155
Multiple Sclerosis - Pipeline by Cellceutix Corp, H2 2016 156
Multiple Sclerosis - Pipeline by Cognosci Inc, H2 2016 157
Multiple Sclerosis - Pipeline by Coherus BioSciences Inc, H2 2016 158
Multiple Sclerosis - Pipeline by Commence Bio Inc, H2 2016 159
Multiple Sclerosis - Pipeline by Compugen Ltd, H2 2016 160
Multiple Sclerosis - Pipeline by Connexios Life Sciences Pvt Ltd, H2 2016 161
Multiple Sclerosis - Pipeline by Critical Outcome Technologies Inc, H2 2016 162
Multiple Sclerosis - Pipeline by CuraVac Inc, H2 2016 163
Multiple Sclerosis - Pipeline by Cyxone AB, H2 2016 164
Multiple Sclerosis - Pipeline by Daiichi Sankyo Company Ltd, H2 2016 165
Multiple Sclerosis - Pipeline by Dimerix Bioscience Pty Ltd, H2 2016 166
Multiple Sclerosis - Pipeline by Dong-A Socio Holdings Co Ltd, H2 2016 167
Multiple Sclerosis - Pipeline by Eisai Co Ltd, H2 2016 168
Multiple Sclerosis - Pipeline by Eli Lilly and Company, H2 2016 169
Multiple Sclerosis - Pipeline by Endece LLC, H2 2016 170
Multiple Sclerosis - Pipeline by Evgen Pharma Plc, H2 2016 171
Multiple Sclerosis - Pipeline by Evotec AG, H2 2016 172
Multiple Sclerosis - Pipeline by F. Hoffmann-La Roche Ltd, H2 2016 173
Multiple Sclerosis - Pipeline by Flex Pharma Inc, H2 2016 174
Multiple Sclerosis - Pipeline by Forward Pharma A/S, H2 2016 175
Multiple Sclerosis - Pipeline by FPRT Bio Inc, H2 2016 176
Multiple Sclerosis - Pipeline by Gemac SA, H2 2016 177
Multiple Sclerosis - Pipeline by Genervon Biopharmaceuticals LLC, H2 2016 178
Multiple Sclerosis - Pipeline by GeNeuro SA, H2 2016 179
Multiple Sclerosis - Pipeline by Genzyme Corp, H2 2016 180
Multiple Sclerosis - Pipeline by GlaxoSmithKline Plc, H2 2016 181
Multiple Sclerosis - Pipeline by Glenmark Pharmaceuticals Ltd, H2 2016 182
Multiple Sclerosis - Pipeline by Glialogix Inc, H2 2016 183
Multiple Sclerosis - Pipeline by Hansa Medical AB, H2 2016 184
Multiple Sclerosis - Pipeline by Harbor Therapeutics Inc, H2 2016 185
Multiple Sclerosis - Pipeline by HitGen LTD, H2 2016 186
Multiple Sclerosis - Pipeline by Humabs BioMed SA, H2 2016 187
Multiple Sclerosis - Pipeline by Hutchison MediPharma Ltd, H2 2016 188
Multiple Sclerosis - Pipeline by Iltoo Pharma, H2 2016 189
Multiple Sclerosis - Pipeline by Immune Response BioPharma Inc, H2 2016 190
Multiple Sclerosis - Pipeline by Immune Therapeutics Inc, H2 2016 191
Multiple Sclerosis - Pipeline by ImmuNext Inc, H2 2016 192
Multiple Sclerosis - Pipeline by Immungenetics AG, H2 2016 193
Multiple Sclerosis - Pipeline by Inception Sciences Inc, H2 2016 194
Multiple Sclerosis - Pipeline by Innate Immunotherapeutics Ltd, H2 2016 195
Multiple Sclerosis - Pipeline by Inovio Pharmaceuticals Inc, H2 2016 196
Multiple Sclerosis - Pipeline by Io Therapeutics Inc, H2 2016 197
Multiple Sclerosis - Pipeline by Jyant Technologies Inc, H2 2016 198
Multiple Sclerosis - Pipeline by Kadimastem Ltd, H2 2016 199
Multiple Sclerosis - Pipeline by Kadmon Corp LLC, H2 2016 200
Multiple Sclerosis - Pipeline by KAHR medical Ltd, H2 2016 201
Multiple Sclerosis - Pipeline by KaloBios Pharmaceuticals Inc, H2 2016 202
Multiple Sclerosis - Pipeline by Kancera AB, H2 2016 203
Multiple Sclerosis - Pipeline by Kareus Therapeutics SA, H2 2016 204
Multiple Sclerosis - Pipeline by Karo Pharma AB, H2 2016 205
Multiple Sclerosis - Pipeline by Karyopharm Therapeutics Inc, H2 2016 206
Multiple Sclerosis - Pipeline by Kissei Pharmaceutical Co Ltd, H2 2016 207
Multiple Sclerosis - Pipeline by KPI Therapeutics Inc, H2 2016 208
Multiple Sclerosis - Pipeline by Kyorin Pharmaceutical Co Ltd, H2 2016 209
Multiple Sclerosis - Pipeline by Lead Discovery Center GmbH, H2 2016 210
Multiple Sclerosis - Pipeline by LFB SA, H2 2016 211
Multiple Sclerosis - Pipeline by Lipocure Ltd, H2 2016 212
Multiple Sclerosis - Pipeline by MacroGenics Inc, H2 2016 213
Multiple Sclerosis - Pipeline by MAKScientific LLC, H2 2016 214
Multiple Sclerosis - Pipeline by Mapi Pharma Ltd, H2 2016 215
Multiple Sclerosis - Pipeline by Marathon Pharmaceuticals LLC, H2 2016 216
Multiple Sclerosis - Pipeline by MedAnnex Ltd, H2 2016 217
Multiple Sclerosis - Pipeline by MedDay SA, H2 2016 218
Multiple Sclerosis - Pipeline by Medestea Research & Production SpA, H2 2016 219
Multiple Sclerosis - Pipeline by MedImmune LLC, H2 2016 220
Multiple Sclerosis - Pipeline by Merck KGaA, H2 2016 221
Multiple Sclerosis - Pipeline by Meta-IQ ApS, H2 2016 222
Multiple Sclerosis - Pipeline by Mitochon Pharmaceuticals Inc, H2 2016 223
Multiple Sclerosis - Pipeline by Mitsubishi Tanabe Pharma Corp, H2 2016 224
Multiple Sclerosis - Pipeline by MorphoSys AG, H2 2016 225
Multiple Sclerosis - Pipeline by Mount Tam Biotechnologies Inc, H2 2016 226
Multiple Sclerosis - Pipeline by Neuralstem Inc, H2 2016 227
Multiple Sclerosis - Pipeline by Neuren Pharmaceuticals Ltd, H2 2016 228
Multiple Sclerosis - Pipeline by Neuronax SAS, H2 2016 229
Multiple Sclerosis - Pipeline by Neurotec Pharma SL, H2 2016 230
Multiple Sclerosis - Pipeline by New World Laboratories Inc, H2 2016 231
Multiple Sclerosis - Pipeline by Novartis AG, H2 2016 232
Multiple Sclerosis - Pipeline by NovImmune SA, H2 2016 233
Multiple Sclerosis - Pipeline by Nuevolution AB, H2 2016 234
Multiple Sclerosis - Pipeline by Ogeda SA, H2 2016 235
Multiple Sclerosis - Pipeline by Omeros Corp, H2 2016 236
Multiple Sclerosis - Pipeline by OncoImmune Inc, H2 2016 237
Multiple Sclerosis - Pipeline by Opexa Therapeutics Inc, H2 2016 238
Multiple Sclerosis - Pipeline by Oryzon Genomics SA, H2 2016 239
Multiple Sclerosis - Pipeline by OSE Immunotherapeutics, H2 2016 240
Multiple Sclerosis - Pipeline by Parvus Therapeutics Inc, H2 2016 241
Multiple Sclerosis - Pipeline by Peptinov SAS, H2 2016 242
Multiple Sclerosis - Pipeline by Pfenex Inc, H2 2016 243
Multiple Sclerosis - Pipeline by Pfizer Inc, H2 2016 244
Multiple Sclerosis - Pipeline by PharmaEssentia Corp, H2 2016 245
Multiple Sclerosis - Pipeline by PharmatrophiX Inc, H2 2016 246
Multiple Sclerosis - Pipeline by Pharmaxis Ltd, H2 2016 247
Multiple Sclerosis - Pipeline by Pieris Pharmaceuticals Inc, H2 2016 248
Multiple Sclerosis - Pipeline by Polleo Pharma Ltd, H2 2016 249
Multiple Sclerosis - Pipeline by ProNoxis AB, H2 2016 250
Multiple Sclerosis - Pipeline by Prothena Corp Plc, H2 2016 251
Multiple Sclerosis - Pipeline by Q Therapeutics Inc, H2 2016 252
Multiple Sclerosis - Pipeline by ReceptoPharm Inc, H2 2016 253
Multiple Sclerosis - Pipeline by RedHill Biopharma Ltd, H2 2016 254
Multiple Sclerosis - Pipeline by RegeneRx Biopharmaceuticals Inc, H2 2016 255
Multiple Sclerosis - Pipeline by Regenesance BV, H2 2016 256
Multiple Sclerosis - Pipeline by Renovo Neural Inc, H2 2016 257
Multiple Sclerosis - Pipeline by Resverlogix Corp, H2 2016 258
Multiple Sclerosis - Pipeline by ReveraGen BioPharma Inc, H2 2016 259
Multiple Sclerosis - Pipeline by Rigel Pharmaceuticals Inc, H2 2016 260
Multiple Sclerosis - Pipeline by Rodos BioTarget GmbH, H2 2016 261
Multiple Sclerosis - Pipeline by SanBio Inc, H2 2016 262
Multiple Sclerosis - Pipeline by Santhera Pharmaceuticals Holding AG, H2 2016 263
Multiple Sclerosis - Pipeline by Sareum Holdings Plc, H2 2016 264
Multiple Sclerosis - Pipeline by Sorrento Therapeutics Inc, H2 2016 265
Multiple Sclerosis - Pipeline by Symic Biomedical Inc, H2 2016 266
Multiple Sclerosis - Pipeline by Synthon Holdings BV, H2 2016 267
Multiple Sclerosis - Pipeline by Targazyme Inc, H2 2016 268
Multiple Sclerosis - Pipeline by Teikoku Pharma USA Inc, H2 2016 269
Multiple Sclerosis - Pipeline by Teva Pharmaceutical Industries Ltd, H2 2016 270
Multiple Sclerosis - Pipeline by Therapix Biosciences Ltd, H2 2016 271
Multiple Sclerosis - Pipeline by TikoMed AB, H2 2016 272
Multiple Sclerosis - Pipeline by Toleranzia AB, H2 2016 273
Multiple Sclerosis - Pipeline by Topas Therapeutics GmbH, H2 2016 274
Multiple Sclerosis - Pipeline by TxCell SA, H2 2016 275
Multiple Sclerosis - Pipeline by Vaccinex Inc, H2 2016 276
Multiple Sclerosis - Pipeline by Vakzine Projekt Management GmbH, H2 2016 277
Multiple Sclerosis - Pipeline by Virogenomics BioDevelopment Inc, H2 2016 278
Multiple Sclerosis - Pipeline by Vitae Pharmaceuticals Inc, H2 2016 279
Multiple Sclerosis - Pipeline by VivaCell Biotechnology Espana SL, H2 2016 280
Multiple Sclerosis - Pipeline by Xenetic Biosciences (UK) Ltd, H2 2016 281
Multiple Sclerosis - Pipeline by XL-protein GmbH, H2 2016 282
Multiple Sclerosis - Pipeline by Yungjin Pharm Co Ltd, H2 2016 283
Multiple Sclerosis - Pipeline by Zenith Capital Corp, H2 2016 284
Multiple Sclerosis - Pipeline by Zydus Cadila Healthcare Ltd, H2 2016 285
Assessment by Monotherapy Products, H2 2016 286
Assessment by Combination Products, H2 2016 287
Number of Products by Stage and Target, H2 2016 289
Number of Products by Stage and Mechanism of Action, H2 2016 305
Number of Products by Stage and Route of Administration, H2 2016 324
Number of Products by Stage and Molecule Type, H2 2016 326
Multiple Sclerosis - Dormant Projects, H2 2016 875
Multiple Sclerosis - Dormant Projects (Contd..1), H2 2016 876
Multiple Sclerosis - Dormant Projects (Contd..2), H2 2016 877
Multiple Sclerosis - Dormant Projects (Contd..3), H2 2016 878
Multiple Sclerosis - Dormant Projects (Contd..4), H2 2016 879
Multiple Sclerosis - Dormant Projects (Contd..5), H2 2016 880
Multiple Sclerosis - Dormant Projects (Contd..6), H2 2016 881
Multiple Sclerosis - Dormant Projects (Contd..7), H2 2016 882
Multiple Sclerosis - Dormant Projects (Contd..8), H2 2016 883
Multiple Sclerosis - Dormant Projects (Contd..9), H2 2016 884
Multiple Sclerosis - Dormant Projects (Contd..10), H2 2016 885
Multiple Sclerosis - Dormant Projects (Contd..11), H2 2016 886
Multiple Sclerosis - Dormant Projects (Contd..12), H2 2016 887
Multiple Sclerosis - Dormant Projects (Contd..13), H2 2016 888
Multiple Sclerosis - Dormant Projects (Contd..14), H2 2016 889
Multiple Sclerosis - Dormant Projects (Contd..15), H2 2016 890
Multiple Sclerosis - Dormant Projects (Contd..16), H2 2016 891
Multiple Sclerosis - Dormant Projects (Contd..17), H2 2016 892
Multiple Sclerosis - Dormant Projects (Contd..18), H2 2016 893
Multiple Sclerosis - Dormant Projects (Contd..19), H2 2016 894
Multiple Sclerosis - Dormant Projects (Contd..20), H2 2016 895
Multiple Sclerosis - Dormant Projects (Contd..21), H2 2016 896
Multiple Sclerosis - Dormant Projects (Contd..22), H2 2016 897
Multiple Sclerosis - Dormant Projects (Contd..23), H2 2016 898
Multiple Sclerosis - Dormant Projects (Contd..24), H2 2016 899
Multiple Sclerosis - Discontinued Products, H2 2016 900
Multiple Sclerosis - Discontinued Products (Contd..1), H2 2016 901
Multiple Sclerosis - Discontinued Products (Contd..2), H2 2016 902
Multiple Sclerosis - Discontinued Products (Contd..3), H2 2016 903
Multiple Sclerosis - Discontinued Products (Contd..4), H2 2016 90
 

List of Figures

List of Figures
Number of Products under Development for Multiple Sclerosis, H2 2016 48
Number of Products under Development for Multiple Sclerosis - Comparative Analysis, H2 2016 49
Number of Products under Development by Companies, H2 2016 50
Number of Products under Investigation by Universities/Institutes, H2 2016 67
Comparative Analysis by Late Stage Development, H2 2016 70
Comparative Analysis by Clinical Stage Development, H2 2016 71
Comparative Analysis by Early Stage Products, H2 2016 72
Assessment by Monotherapy Products, H2 2016 286
Number of Products by Top 10 Targets, H2 2016 288
Number of Products by Stage and Top 10 Targets, H2 2016 288
Number of Products by Top 10 Mechanism of Actions, H2 2016 304
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 304
Number of Products by Top 10 Routes of Administration, H2 2016 323
Number of Products by Stage and Top 10 Routes of Administration, H2 2016 323
Number of Products by Top 10 Molecule Types, H2 2016 325
Number of Products by Stage and Top 10 Molecule Types, H2 2016 325
 

Scope


- The pipeline guide provides a snapshot of the global therapeutic landscape of Multiple Sclerosis (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Multiple Sclerosis (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Multiple Sclerosis (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Multiple Sclerosis (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Multiple Sclerosis (Central Nervous System)

 

Highlights

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Multiple Sclerosis - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Multiple Sclerosis (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Multiple Sclerosis (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Multiple Sclerosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 5, 9, 30, 32, 173, 36 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 4, 46 and 2 molecules, respectively.

Multiple Sclerosis (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

 

Classification

Language Code: EN 
Region: Global 
Report Type: Market Report 
Industry: Life Sciences 
Sector: Central Nervous System 
Pages: 928 

Companies Featured

2-BBB Medicines BV 4D Pharma Plc AB Science SA AbbVie Inc Abion Inc Ablynx NV Abzena Plc Acorda Therapeutics Inc Actelion Ltd Adamas Pharmaceuticals Inc Addex Therapeutics Ltd Adhaere Pharmaceuticals Inc Aegis Therapeutics LLC Affectis Pharmaceuticals AG AiCuris GmbH & Co KG Alkermes Plc Alpha Cancer Technologies Inc Amarna Therapeutics BV Anavex Life Sciences Corp Antisense Therapeutics Ltd Aphios Corp Apitope International NV ARA Healthcare Pvt Ltd Arena Pharmaceuticals Inc arGEN-X BV Argos Therapeutics Inc Arrien Pharmaceuticals LLC Artielle ImmunoTherapeutics Inc Astellas Pharma Inc Asterias Biotherapeutics Inc Atara Biotherapeutics Inc Athersys Inc Atlantic Bio Sci LLC Axxam SpA Baliopharm AG Bio-Cancer Treatment International Ltd BioAegis Therapeutics Inc BioApex sro Biocad Biocon Ltd Biogen Inc Biogenomics Ltd BioHealthonomics Inc Biokine Therapeutics Ltd Biomar Microbial Technologies Bioncotech Therapeutics SL Bionovis SA Bionure Farma SL Biovista Inc Bolder Biotechnology Inc BrainStorm Cell Therapeutics Inc Bristol-Myers Squibb Company C4X Discovery Holdings PLC CASI Pharmaceuticals Inc Catalyst Pharmaceuticals Inc Celgene Corp Cell Cure Neurosciences Ltd Cell2B Advanced Therapeutics SA Cellceutix Corp Cognosci Inc Coherus BioSciences Inc Commence Bio Inc Compugen Ltd Connexios Life Sciences Pvt Ltd Critical Outcome Technologies Inc CuraVac Inc Cyxone AB Daiichi Sankyo Company Ltd Dimerix Bioscience Pty Ltd Dong-A Socio Holdings Co Ltd Eisai Co Ltd Eli Lilly and Company Endece LLC Evgen Pharma Plc Evotec AG F. Hoffmann-La Roche Ltd Flex Pharma Inc Forward Pharma A/S FPRT Bio Inc Gemac SA Genervon Biopharmaceuticals LLC GeNeuro SA Genzyme Corp GlaxoSmithKline Plc Glenmark Pharmaceuticals Ltd Glialogix Inc Hansa Medical AB Harbor Therapeutics Inc HitGen LTD Humabs BioMed SA Hutchison MediPharma Ltd Iltoo Pharma Immune Response BioPharma Inc Immune Therapeutics Inc ImmuNext Inc Immungenetics AG Inception Sciences Inc Innate Immunotherapeutics Ltd Inovio Pharmaceuticals Inc Io Therapeutics Inc Jyant Technologies Inc Kadimastem Ltd Kadmon Corp LLC KAHR medical Ltd KaloBios Pharmaceuticals Inc Kancera AB Kareus Therapeutics SA Karo Pharma AB Karyopharm Therapeutics Inc Kissei Pharmaceutical Co Ltd KPI Therapeutics Inc Kyorin Pharmaceutical Co Ltd Lead Discovery Center GmbH LFB SA Lipocure Ltd MacroGenics Inc MAKScientific LLC Mapi Pharma Ltd Marathon Pharmaceuticals LLC MedAnnex Ltd MedDay SA Medestea Research & Production SpA MedImmune LLC Merck KGaA Meta-IQ ApS Mitochon Pharmaceuticals Inc Mitsubishi Tanabe Pharma Corp MorphoSys AG Mount Tam Biotechnologies Inc Neuralstem Inc Neuren Pharmaceuticals Ltd Neuronax SAS Neurotec Pharma SL New World Laboratories Inc Novartis AG NovImmune SA Nuevolution AB Ogeda SA Omeros Corp OncoImmune Inc Opexa Therapeutics Inc Oryzon Genomics SA OSE Immunotherapeutics Parvus Therapeutics Inc Peptinov SAS Pfenex Inc Pfizer Inc PharmaEssentia Corp PharmatrophiX Inc Pharmaxis Ltd Pieris Pharmaceuticals Inc Polleo Pharma Ltd ProNoxis AB Prothena Corp Plc Q Therapeutics Inc ReceptoPharm Inc RedHill Biopharma Ltd RegeneRx Biopharmaceuticals Inc Regenesance BV Renovo Neural Inc Resverlogix Corp ReveraGen BioPharma Inc Rigel Pharmaceuticals Inc Rodos BioTarget GmbH SanBio Inc Santhera Pharmaceuticals Holding AG Sareum Holdings Plc Sorrento Therapeutics Inc Symic Biomedical Inc Synthon Holdings BV Targazyme Inc Teikoku Pharma USA Inc Teva Pharmaceutical Industries Ltd Therapix Biosciences Ltd TikoMed AB Toleranzia AB Topas Therapeutics GmbH TxCell SA Vaccinex Inc Vakzine Projekt Management GmbH Virogenomics BioDevelopment Inc Vitae Pharmaceuticals Inc VivaCell Biotechnology Espana SL Xenetic Biosciences (UK) Ltd XL-protein GmbH Yungjin Pharm Co Ltd Zenith Capital Corp Zydus Cadila Healthcare Ltd

 

Reasons to buy this report


- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Multiple Sclerosis (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Multiple Sclerosis (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
 

Similar Reports

Other reports that may be of interest...

Report... 05IB-GMDHC8907IDBMultiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-Sys...Dec 2016
Report... 05IB-GMDHC8884IDBProgressive Relapsing Multiple Sclerosis (PRMS) - Pipeline Revie...Dec 2016
Report... 05IB-GMDHC8855IDBProgressive Supranuclear Palsy - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8863IDBParkinson's Disease - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8861IDBNeuropathic Pain - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8832IDBSmoking Addiction - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8797IDBInfantile Spasm (West Syndrome) - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8796IDBMetachromatic Leukodystrophy (MLD) - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8799IDBEssential Tremor - Pipeline Review, H2 2016Dec 2016

Multiple Sclerosis - Pipeline Review, H2 2016

Report 05IB-GMDHC8845IDB has a rating of 96 percent
Figure of merit assessment for report 05IB-GMDHC8845IDB

Relevance Rating

The Research and Experts relevance ranting consists of a set of figure of merit (FOM) values that are provided as an indication of the value of the report in the current economic environment.

These FOM values cannot take into account the reason for the clients interest in a report and therefore the client should view these FOM values only as a visual guide. The FOM scores are based on

market interest - how often the report is viewed or purchased,
elapsed time - time since the report was published,
report detail - amount of detail in the report (pages, figures, images, comments etc.) and
price - the price of the report.


Regional Information

Taxonomy

Branch ID: 1591

Taxonomy Location

The taxonomy on the left shows the ancestors of the Global node. This provides an insight into parent categories that may provide reports or articles that may compliment this report. The number in brackets after the node name indicates the number of reports that Research and Experts currently have in the parent category.

Clicking on a parent category will present the list of reports in the parent node in a separate window.

Global

The global economy is the economy of all the world's countries. The total world population now stands at over 7 billion and the global unemployment rate is 9% with approximately half the world's population paid less than $2 a day. 

The global economy is picking up again after five years of uncertaintity and slow economic growth. The IMF is predicting global growth of 3.7% in 2014 rising to 3.9% in 2015. However, much uncertainity remains. Low inflation in developed economies means that these economies take longer to deal with debt burdens and are at increases risk of deflation. 

The second half of 2013 saw growth in the US and European economies (particularly UK, Germany and France).  

Growth in the US has been helped by cheaper energy from fracking , renewables and more oil and gas exploration. This cheaper energy is bring manufacturing jobs back to the US and helping to boost domestic demand. Recent winter weather conditions have hampered growth in the construction sector and have slowed demand in the construction equipment sector which saw exports drop by 25% in 2013. Growth should pick up in this sector with continued federal investment in infrastructure, new residential house builds and refurbishment and the energy boom.

In Europe growth is expected to be uneven with growth being slow in stressed economies such as Portugal and Greece but confidence picking up in UK, Ireland and even Spain showing some improvement.

Developing economies such as China and India will continue to have strong growth in 2014 and 2015. China has benefitted from increased investment with the Chinese govenment now focused on quality growth of 7.5% in 2014. India which is less reliant on exports expects growth of 5.4% in 2014 and 6.4% in 2015.

Much uncertainity still remains in the global economy with greater optimism needed to stabilise growth.

Links

World Bank

IMF (International Monetary Fund)

 

 

Zones

Regional zones

 

Country

Countries

 

Industry Sector Information

Taxonomy

Branch ID: 7188

Taxonomy Location

The taxonomy on the left shows the ancestors of the Central Nervous System node. This provides an insight into parent categories that may provide reports or articles that may compliment this report. The number in brackets after the node name indicates the number of reports that Research and Experts currently have in the parent category.

Clicking on a parent category will present the list of reports in the parent node in a separate window.

Central Nervous System

Central Nervous System

 

Healthcare

The healthcare industry is changing rapidly due to changes in legislation (US Affordable Healthcare Act),  advances in IT and more pressures on governments and healthcare providers due to rising costs. 

According to a recent report by the OECD healthcare spending has fallen in one third of OECD member states due to the credit crunch and members are facing up to the challenge of providing greater care with fewer resources. Spending on healthcare has increased in Japan, Israel and Korea while it has dropped dramatically in Greece and Ireland.

Useful Links

World Health Organisation 

American Healthcare Association

The British Healthcare Business Intelligence Association

OECD, Health Policies and Data

Healthcare

Life Sciences

The Life Sciences industry includes biotechnology, healthcare, pharmaceuticals, medical devices and diagnostics. The industry is dominated by US companies requiring considerable investment in research and development to stay competitive.  While US companies dominate this space, competition is emerging from smaller companies in Europe and Asia. 

Companies trying to stay competitive or enter new markets in life sciences consult our reports. For example, Plimsoll, in their recent review of global antibiotic manufacturers have reviewed 150 of the largest manufacturers including analysis of  ANTIBIOTICE SA, BAYER HEALTHCARE MANUFACTURING SRL and CIPLA LTD. 

Our reports are a requirement for companies looking for the best competitive intelligence in the life sciences sector providing information on market size, rankings, best trading partners and financial analysis. 

Useful Links

Analytical Life Sciences and Diagnostics Association

German Life Sciences Association

 

Life Sciences

Industry

Industries

 

 

Buy: Multiple Sclerosis - Pipeline Review, H2 2016

 

Item Code: 05IB-GMDHC8845IDB

 
Licence: Single User
Price: $2500.00
 
VAT: 0.0% 
Total: $2500.00 

Feedback

Return to Research and Experts

Page created and rendered - Cache updated [0.15184s]

--